Hemophilia B Treatments
Find Hemophilia B Treatments
Brand Name
Hympavzi
Generic Name
Marstacimab-Hncq
View Brand Information FDA approval date: November 05, 2024
Form: Injection
What is Hympavzi (Marstacimab-Hncq)?
HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with: hemophilia A with or without factor VIII inhibitors, or, hemophilia B with or without factor IX inhibitors. HYMPAVZI is a tissue factor pathway inhibitor antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with:, hemophilia A with or without factor VIII inhibitors, or, hemophilia B with or without factor IX inhibitors.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
Objectives: o quantify patient preferences for subcutaneous versus intravenous (IV) injection using the Marstacimab-Patient Preference Questionnaire (M-PPQ) after 1 month of marstacimab for routine prophylaxis treatment. To assess the treatment burden using the Hemophilia Treatment Experience Measure (Hemo-TEM) in hemophilia patients after 6 months of marstacimab for routine prophylaxis treatment. Exploratory...